- Home
- NNNN vs IDYA Comparison
NNNN vs IDYA Comparison
Compare NNNN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNNN
- IDYA
- Stock Information
- Founded
- NNNN 2021
- IDYA 2015
- Country
- NNNN Germany
- IDYA United States
- Employees
- NNNN N/A
- IDYA N/A
- Industry
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- NNNN Health Care
- IDYA Health Care
- Exchange
- NNNN Nasdaq
- IDYA Nasdaq
- Market Cap
- NNNN 2.2B
- IDYA 2.3B
- IPO Year
- NNNN 2025
- IDYA 2019
- Fundamental
- Price
- NNNN $28.10
- IDYA $27.13
- Analyst Decision
- NNNN
- IDYA Buy
- Analyst Count
- NNNN 0
- IDYA 15
- Target Price
- NNNN N/A
- IDYA $47.92
- AVG Volume (30 Days)
- NNNN 82.0K
- IDYA 1.2M
- Earning Date
- NNNN 10-23-2025
- IDYA 11-03-2025
- Dividend Yield
- NNNN N/A
- IDYA N/A
- EPS Growth
- NNNN N/A
- IDYA N/A
- EPS
- NNNN 0.06
- IDYA N/A
- Revenue
- NNNN $8,185,146.00
- IDYA $7,000,000.00
- Revenue This Year
- NNNN N/A
- IDYA $63.41
- Revenue Next Year
- NNNN N/A
- IDYA $305.49
- P/E Ratio
- NNNN $566.20
- IDYA N/A
- Revenue Growth
- NNNN 21.95
- IDYA N/A
- 52 Week Low
- NNNN $5.18
- IDYA $13.45
- 52 Week High
- NNNN $55.65
- IDYA $32.67
- Technical
- Relative Strength Index (RSI)
- NNNN 38.40
- IDYA 59.05
- Support Level
- NNNN $28.13
- IDYA $26.77
- Resistance Level
- NNNN $33.32
- IDYA $27.59
- Average True Range (ATR)
- NNNN 5.89
- IDYA 0.94
- MACD
- NNNN -0.54
- IDYA -0.01
- Stochastic Oscillator
- NNNN 26.27
- IDYA 55.48
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.